RxDoctor Payments Data

Teresa Murphree

Family · Germantown, TNNPI 1013393958

Payments from drug & device makers

$762in general payments, 2019–2025

Across 35 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$203
  • Pfizer$113
  • Heartflow, Inc.$107
  • Amarin Pharma, Inc.$82
  • AstraZeneca$44
  • Actelion Pharmaceuticals US, Inc.$37
  • plus $175 from 6 others

What the payments were for

  • Food & beverage$762100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$762 in reported general payments places this provider in the 55th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$33,533
Medicare patients
326
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan60$73,214
EliquisApixaban58$57,714
JardianceEmpagliflozin39$48,009
Repatha SureclickEvolocumab13$19,830
XareltoRivaroxaban15$19,633
Ranolazine ErRanolazine49$2,740
Atorvastatin Calcium113$1,583
Metoprolol Succinate88$1,311
Losartan Potassium97$1,111
Ezetimibe40$1,016
Hydralazine Hcl64$872
Amlodipine Besylate123$822
Carvedilol117$788
Amiodarone Hcl33$739
Midodrine Hcl12$629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$203$73,21460 claims
PfizerEliquis$113$57,71458 claims
Johnson & JohnsonXarelto$16$19,63315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,706 family providers in Tennessee.

Other family in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →